Novo Nordisk A/s

Novo Nordisk Healthcare Ag

Henrik Oestergaard

Prafull S Gandhi

Ole Hvilsted Olsen

Jens Breinholt

Carsten Behrens

Henning Ralf Stennicke

Jianhe Chen

Laust Bruun Johnsen

Rong Zhou

Karina Thorn

Per J Greisen

Mikkel Nors Harndahl

Zhiru Yang

Bjarne Gram Hansen

Morten Groenbech Rasch

Haisun Zhu

Paul L DeAngelis

Ida Hilden

Anders Svensson

Jes Thorn Clausen

Mikael Kofod-Hansen

Soeren Oestergaard

Kasper Lamberth

Eva Johansson

Friedrich Michael Haller

Heidi Lindgreen Holmberg

The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.

Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies

The present invention relates to improved procoagulant antibodies including bispecific antibodies capable of binding to coagulation Factor IX (FIX) or the activated form thereof Factor IXa (FIXa) and optionally Factor X (FX) and the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A.

Procoagulant antibodies

Bispecific antibodies

The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

The present invention relates to the conjugation of Factor VII polypeptides with heparosan polymers. The resultant conjugates may be used to deliver Factor VII, for example in the treatment or prevention of bleeding disorders.

Factor VII conjugates

The present invention relates to modified coagulation Factor VII polypeptides exhibiting increased resistance to antithrombin inactivation and enhanced proteolytic activity. The present invention also relates to polynucleotide constructs encoding such polypeptides, vectors and host cells comprising and expressing such polynucleotides, pharmaceutical compositions, uses and methods of treatment.

Coagulation factor VII polypeptides

The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A.

Therapeutic factor VIII antibodies

A method of selectively introducing a substituent into a protein proximal to a binding site on the protein for a homing peptide, comprising: (a) contacting the protein with a compound comprising a homing peptide having the ability to bind to the binding site of the protein; and (b) allowing a moiety on the protein proximal to the binding site to react with the compound comprising the homing peptide, thereby to transfer the substituent G onto the protein.

Selective modification of proteins

Growing community of inventors

Oelstykke, Denmark

Henrik Oestergaard